Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.

@article{Fayad2015DacetuzumabPR,
  title={Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.},
  author={Luis E. Fayad and Stephen M Ansell and Ranjana Hira Advani and Bertrand Coiffier and Robert K. Stuart and Nancy L. Bartlett and Andres Forero-Torres and Kazimierz Kuliczkowski and David Belada and Edmund Ng and Jonathan G. Drachman},
  journal={Leukemia & lymphoma},
  year={2015},
  volume={56 9},
  pages={2569-78}
}
Single-agent dacetuzumab has demonstrated antitumor activity in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Preclinical data demonstrated improved dacetuzumab antitumor activity in combination with rituximab, ± chemotherapy. We designed a phase 2b, double-blind, placebo-controlled trial to compare rituximab, ifosfamide, carboplatin and etoposide (R-ICE) + dacetuzumab with R-ICE + placebo in patients with DLBCL who relapsed after rituximab, cyclophosphamide, doxorubicin… CONTINUE READING